Novartis: lung function improved in asthma patients

(CercleFinance.com) - Novartis said its new inhaled combination treatment for asthma improves lung function compared to the standard of care, according to phase II data.


In two phase II clinical studies, the QVM149 formulation was superior to the comparators, almeterol/fluticasone propionate and placebo, separately by demonstrating improvement in lung function in patients with asthma.

In another phase II study, the treatment met the primary endpoint with statistically significant improvements of forced expiratory volume, the drugmaker said.

These results demonstrate that the combination offering dual bronchodilation plus an inhaled corticosteroid can provide lung function benefits to patients with asthma beyond established therapies, Novartis said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.